Editorially independent · We do not sell peptides

5-Amino-1MQ

NNMT (nicotinamide N-methyltransferase) inhibitor · investigational metabolic modulator

EVIDENCE GRADE
D
Anecdotal
TYPE
Metabolic
EU
NOT AUTHORISED
US
NOT AUTHORISED
MOLECULAR INFORMATION

Molecular information

Type
NNMT (nicotinamide N-methyltransferase) inhibitor · investigational metabolic modulator

5-Amino-1MQ is a research-stage NNMT inhibitor sold grey-market alongside peptides despite being a small molecule.

Claims vs evidence

  • NNMT inhibition / SAM restoration — biochemistry well-characterised
  • Fat-loss / metabolic improvement — rodent data only
  • Body-composition change in humans — no trial

Why we grade it D

Promising preclinical mechanism, zero human evidence. Grey-market vendors price it as a fat-loss aid with no clinical support for that claim.

Frequently asked questions

What is 5-Amino-1MQ?
A small-molecule (technically not a peptide) inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT consumes the methyl donor SAM and is elevated in obesity; inhibiting it is proposed as a strategy to increase SAM availability and metabolic flexibility.
Is 5-Amino-1MQ a peptide?
No — it is a small molecule. Listed here because grey-market peptide vendors stock it alongside peptides and readers expect coverage.
Is it authorised?
No — preclinical research compound. Mouse data showed fat-loss and metabolic improvement; no human trials registered.
Related compounds

Other compounds in this category